

# Strengthening patient 's pathways for a better hepatitis C (HCV ) cascade care in most vulnerable populations: The HCV "Parcours "Project in Ile de France (IDF)

## Authors

Dominguez S<sup>1</sup>, Bachelard A<sup>1</sup>, Avril E<sup>2</sup>, Dullioust A<sup>3</sup>, Fac C<sup>4</sup>, Salmon D<sup>5</sup>, Lacombe K<sup>6</sup>, Simon A<sup>7</sup>, Fontaine H<sup>8</sup>, Hezode C<sup>1</sup>, Roulot D<sup>9</sup>, Chevaliez S<sup>1</sup>, Roudot Thoraval F<sup>1</sup>

<sup>1</sup>Henri Mondor Hospital, <sup>2</sup>CSAPA GAIA, <sup>3</sup>Etablissement publique de santé nationale de Fresnes, <sup>4</sup>Maison d'arrêt de Fresnes, <sup>5</sup>Hôtel Dieu Hospital, <sup>6</sup>Saint Antoine Hospital, <sup>7</sup>Pitié Salpetriere Hospital, <sup>8</sup>Cochin Hospital, <sup>9</sup>Avicenne Hospital,

## Background

With current highly effective direct-acting antiviral (DAAs) and shortened treatment duration, screening, access to DAAs and retention in care have become the new challenges in difficult to reach populations as migrants or people who inject drugs.

## Methods

Large pilot study in the Parisian area:

- Create a large network for the collaboration of:
  - Care settings for injection drug users and vulnerable people, medical units for prisoners, GPs involved in opioid substitution
  - Reference centres (hospitals) where treatments are prescribed
- Improve cascade of care:
  - Strong promotion of testing
  - Rapid link to care: consultation with specialist within  $\leq 1$  week
  - Help from social mediators, nurses in therapeutic education

## Results


### Analysis of intermediate results at 15 months for 488 cases

#### ▪ Patient characteristics


488 patients	
Male	422 (86.5%)
Median age (range) years	45.7 (37-51)
Exposition Risk to HCV	
History of injection drug use	81%
OST	67.4%
Migrants from high endemic areas	28.7%
Imprisoned	17.6%
Comorbidities	
Psychiatric comorbidities	38%
HIV	19%
HIV	7.4%
HBV	3.1%

#### ▪ Fibrosis score distribution

Fibrosis stage (n=297)  
Evaluation by FibroScan® or FibroTest®



#### ▪ HCV Cascade Care to date



#### ▪ Predictive factors for leaving the HCV care path

Univariate analysis	P-value
Serology duration	0.058
Imprisoned	<0.001
Born in a European Union country	<0.001
Lack of social coverage	<0.001
Multivariate analysis	
OR (95% CI) P	
Imprisoned	2.8 (1.39-5.65) (P=0.004)
Born in a European Union country	2.44 (1.02-5.85) (P=0.045)

## Conclusion

Personalized pathway in difficult to reach patients and coordination with dedicated team are needed with special efforts for the follow up of prisoners after detention.

Disclosure of Interest Statement: None Declared

